An update of recent trials with vildagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.

Authors
Category Systematic review
JournalJournal of Pharmacy Technology
Year 2009
This article has no abstract
Epistemonikos ID: b9359d2aea5ef4d04f0103ed98f0b93657a42fe2
First added on: Apr 24, 2019